Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HTC-867 Administered Orally to Healthy Japanese Male Subjects.
Latest Information Update: 08 Nov 2021
At a glance
- Drugs HTC 867 (Primary)
- Indications Cognition disorders
- Focus Adverse reactions
- 31 Dec 2010 New trial record